Related Experiment Videos
An evaluation of total parenteral nutrition using Vamin and Aminosyn as protein base in critically ill preterm
Insights
Total parenteral nutrition (TPN) in preterm infants can cause liver dysfunction and bone disease. Limiting protein intake to less than 2.5 g/kg/day and monitoring infants closely is recommended.
Area of Science:
- Neonatalogy
- Pediatric Nutrition
- Clinical Pharmacy
Background:
- Preterm infants (<32 wk gestation) often require Total Parenteral Nutrition (TPN).
- TPN can lead to complications like cholestasis and metabolic bone disease.
- Monitoring for TPN-induced complications is crucial in this vulnerable population.
Purpose of the Study:
- To evaluate the incidence and severity of TPN-induced liver dysfunction, cholestatic jaundice, and metabolic bone disease in preterm infants.
- To compare the efficacy of Vamin versus Aminosyn as protein bases in TPN.
- To identify risk factors and suggest management guidelines for TPN-related complications.
Main Methods:
- Retrospective analysis of 75 preterm infants (<32 wk gestation) receiving TPN for >20 days.
- Monitoring for liver dysfunction, cholestatic jaundice, and osteopenia of prematurity.
- Assessment of protein intake (Vamin vs. Aminosyn) and TPN duration.
Main Results:
- TPN-induced cholestasis severity correlated with TPN duration and protein quantity.
- Vamin appeared superior to Aminosyn as a protein base.
- TPN-induced metabolic bone disease strongly correlated with TPN duration.
Conclusions:
- Close monitoring for liver dysfunction, cholestatic jaundice, and bone disease is essential in preterm infants on TPN.
- Intravenous protein intake should be limited to <2.5 g/kg/day for preterm infants (<32 wk gestation).
- Individualized TPN management is critical to minimize complications.
Abstract:
A total of 75 preterm infants with gestation less than 32 wk received total parenteral nutrition (TPN) using Vamin and Aminosyn as protein base lasting more than 20 days. They were monitored for signs of liver dysfunction, cholestatic jaundice, and TPN-induced metabolic bone disease (osteopenia of prematurity). It was observed that severity of TPN-induced cholestasis depends on the duration of TPN and quantity of protein infused. When used as a protein base, Vamin seemed to be superior to Aminosyn. TPN-induced metabolic bone disease was strongly correlated to the duration of TPN. We suggest close monitoring of critically ill preterm infants on TPN for quantity of protein infusate, liver dysfunction, cholestatic jaundice, and TPN-induced metabolic bone disease. Intravenous protein intake should be limited to less than 2.5 g/kg/day in preterm infants with gestation less than 32 wk.